Nanomedicine in the treatment of Glioblastoma

Syeda Kubra Kishwar Jafri; Syed Sarmad Bukhari; Muhammad Shahzad Shamim

Nanomedicine in the treatment of Glioblastoma

Syeda Kubra Kishwar Jafri, Syed Sarmad Bukhari, Muhammad Shahzad Shamim

Department of Surgery, Medical College, Pakistan

Research output: Contribution to journal › Article › peer-review

Abstract

The current standard of care in glioblastoma management is surgery followed by chemotherapy and radiotherapy. Temozolomide is an alkylating agent most commonly used with a few other second line options. The efficacy of systemic chemotherapy in brain malignancies is limited due to the nature of the blood-brain barrier. Nanomedicine offers one avenue of improving drug delivery to these tumours in a more focussed and effective way in higher doses than currently possible, while simultaneously reducing systemic toxicity.

Original language	English
Pages (from-to)	2678
Number of pages	1
Journal	JPMA. The Journal of the Pakistan Medical Association
Volume	71
Issue number	11
Publication status	Published - 1 Nov 2021

Keywords

Glioblastoma multiforme, brain tumour, nanotechnology

Cite this

@article{aaf4489498c04d39a03ced9b2f12e1e2,

title = "Nanomedicine in the treatment of Glioblastoma",

abstract = "The current standard of care in glioblastoma management is surgery followed by chemotherapy and radiotherapy. Temozolomide is an alkylating agent most commonly used with a few other second line options. The efficacy of systemic chemotherapy in brain malignancies is limited due to the nature of the blood-brain barrier. Nanomedicine offers one avenue of improving drug delivery to these tumours in a more focussed and effective way in higher doses than currently possible, while simultaneously reducing systemic toxicity.",

keywords = "Glioblastoma multiforme, brain tumour, nanotechnology",

author = "{Kishwar Jafri}, {Syeda Kubra} and Bukhari, {Syed Sarmad} and Shamim, {Muhammad Shahzad}",

year = "2021",

month = nov,

day = "1",

language = "English",

volume = "71",

pages = "2678",

journal = "JPMA. The Journal of the Pakistan Medical Association",

issn = "0030-9982",

publisher = "Pakistan Medical Association",

number = "11",

}

TY - JOUR

T1 - Nanomedicine in the treatment of Glioblastoma

AU - Kishwar Jafri, Syeda Kubra

AU - Bukhari, Syed Sarmad

AU - Shamim, Muhammad Shahzad

PY - 2021/11/1

Y1 - 2021/11/1

N2 - The current standard of care in glioblastoma management is surgery followed by chemotherapy and radiotherapy. Temozolomide is an alkylating agent most commonly used with a few other second line options. The efficacy of systemic chemotherapy in brain malignancies is limited due to the nature of the blood-brain barrier. Nanomedicine offers one avenue of improving drug delivery to these tumours in a more focussed and effective way in higher doses than currently possible, while simultaneously reducing systemic toxicity.

AB - The current standard of care in glioblastoma management is surgery followed by chemotherapy and radiotherapy. Temozolomide is an alkylating agent most commonly used with a few other second line options. The efficacy of systemic chemotherapy in brain malignancies is limited due to the nature of the blood-brain barrier. Nanomedicine offers one avenue of improving drug delivery to these tumours in a more focussed and effective way in higher doses than currently possible, while simultaneously reducing systemic toxicity.

KW - Glioblastoma multiforme, brain tumour, nanotechnology

UR - http://www.scopus.com/inward/record.url?scp=85121960709&partnerID=8YFLogxK

M3 - Article

C2 - 34783762

AN - SCOPUS:85121960709

SN - 0030-9982

VL - 71

SP - 2678

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

IS - 11

ER -

Nanomedicine in the treatment of Glioblastoma

Abstract

Keywords

Other files and links

Fingerprint

Cite this